Select All | Select None
Login failed. Please try again.
Forgot your password?
Log in with Facebook
Log in with Google
You can now keep track of new articles from European Heart Journal Supplements on your personalized homepage!
The ONTARGET Trial Programme includes the ONTARGET and TRANSCEND studies. In both studies, participants were at high cardiovascular risk because they had vascular disease without heart failure, or diabetes with end-organ damage. Participants also received proven therapies for cardiovascular risk...
ONTARGET compared the angiotensin II receptor blocker telmisartan with the angiotensin-converting enzyme (ACE) inhibitor ramipril, and the two agents in combination with ramipril alone, in a broad cross section of patients with vascular disease or high-risk diabetes without heart failure....
ONTARGET showed equivalent cardiovascular outcomes from further blood pressure lowering (from near normal) by ramipril, telmisartan, or their combination in over 25 000 well treated high risk randomized subjects. Data from all subjects were pooled to examine the relation between baseline, or...
Treatment of hypertension may represent the most cost-effective strategy for reducing the burden of stroke for patients as well as for healthcare systems. In large clinical trials, angiotensin II receptor blockers (ARBs) and angiotensin-converting enzyme (ACE) inhibitors have demonstrated...
Blockade of the renin–angiotensin system (RAS) with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers (ARBs) has been shown to reduce cardiovascular mortality and morbidity in various patient populations. The recent ONgoing Telmisartan Alone and in combination with...
The renin–angiotensin system (RAS) has been a drug target of particular interest because of its involvement in the cardiovascular and renal disease progression. The angiotensin-converting enzyme (ACE) inhibitors and the selective angiotensin II receptor blockers (ARBs) inhibit the RAS by...
Progressive decline of renal function in chronic kidney disease (CKD), measured by a reduced glomerular filtration rate or albuminuria, is linked to an increased risk of cardiovascular (CV) disease. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), most...
An overwhelming body of evidence has shown that lowering blood pressure (BP) reduces the risk of cardiovascular events, irrespective of the mechanism of action of the agent. Consistent control of BP is of crucial importance. Treatment should effectively lower BP both in the office and out of the...
results per page
Save this article to read later. You can see your Read Later on your DeepDyve homepage.
To save an article, log in first, or sign up for a DeepDyve account if you don't already have one.
Sign Up Log In
To subscribe to email alerts, please log in first, or sign up for a DeepDyve account if you don't already have one.
Read and print from thousands of top scholarly journals.
Sign up with Facebook
Sign up with Google
Already have an account? Log in
To get new article updates from a journal on your personalized homepage, please log in first, or sign up for a DeepDyve account if you don't already have one.